X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (2258) 2258
hematology (1499) 1499
oncology (1466) 1466
index medicus (1333) 1333
male (1281) 1281
female (1276) 1276
middle aged (1132) 1132
adult (1126) 1126
chemotherapy (906) 906
antineoplastic combined chemotherapy protocols - therapeutic use (818) 818
aged (727) 727
high-dose chemotherapy (721) 721
treatment outcome (720) 720
high-dose cytarabine (702) 702
transplantation (694) 694
adolescent (661) 661
cancer (619) 619
bone-marrow-transplantation (557) 557
prognosis (550) 550
non-hodgkins-lymphoma (538) 538
cytarabine - administration & dosage (486) 486
acute myelogenous leukemia (456) 456
transplantation, autologous (455) 455
stem-cell transplantation (442) 442
disease-free survival (419) 419
stem cells (417) 417
combined modality therapy (407) 407
lymphomas (402) 402
care and treatment (395) 395
remission induction (392) 392
high-dose therapy (381) 381
hematopoietic stem cell transplantation (366) 366
high-dose methotrexate (357) 357
therapy (357) 357
retrospective studies (355) 355
recurrence (344) 344
child (334) 334
acute myeloid-leukemia (331) 331
bone-marrow transplantation (329) 329
immunology (311) 311
antineoplastic combined chemotherapy protocols - administration & dosage (293) 293
rituximab (293) 293
survival rate (290) 290
survival analysis (288) 288
medicine & public health (283) 283
young adult (271) 271
antineoplastic combined chemotherapy protocols - adverse effects (266) 266
lymphoma (265) 265
stem cell transplantation (259) 259
salvage therapy (251) 251
leukemia (242) 242
acute myeloid leukemia (241) 241
risk factors (241) 241
survival (239) 239
etoposide - administration & dosage (238) 238
antineoplastic agents - therapeutic use (236) 236
hematopoietic stem cells (236) 236
cytarabine (232) 232
leukemia, myeloid, acute - drug therapy (229) 229
follow-up studies (228) 228
child, preschool (225) 225
hematology, oncology and palliative medicine (214) 214
colony-stimulating factor (213) 213
acute lymphoblastic-leukemia (211) 211
phase-ii (211) 211
hematopoietic stem cell transplantation - methods (209) 209
cyclophosphamide - administration & dosage (205) 205
cyclophosphamide (202) 202
health aspects (201) 201
primary cns lymphoma (199) 199
research (199) 199
etoposide (194) 194
lymphoma, non-hodgkin - therapy (193) 193
acute disease (188) 188
methotrexate (187) 187
analysis (185) 185
cytarabine - therapeutic use (181) 181
pharmacology & pharmacy (174) 174
children (169) 169
leukemia, myeloid, acute - therapy (169) 169
transplantation, homologous (165) 165
relapse (164) 164
methotrexate - administration & dosage (163) 163
trial (163) 163
radiotherapy (161) 161
lymphoma, non-hodgkin - drug therapy (159) 159
acute nonlymphocytic leukemia (151) 151
leukemia, myeloid, acute - mortality (151) 151
transplantation conditioning - methods (148) 148
aged, 80 and over (147) 147
bone marrow transplantation (147) 147
patient outcomes (147) 147
dose-response relationship, drug (146) 146
cytarabine - adverse effects (145) 145
infant (143) 143
drug administration schedule (142) 142
minimal residual disease (142) 142
autologous stem cell transplantation (139) 139
non-hodgkin's lymphomas (139) 139
disease (138) 138
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2706) 2706
German (24) 24
French (10) 10
Russian (10) 10
Spanish (7) 7
Hungarian (2) 2
Japanese (2) 2
Korean (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


EXPERT REVIEW OF CLINICAL PHARMACOLOGY, ISSN 1751-2433, 2019, Volume 12, Issue 3, pp. 197 - 218
Journal Article
Lancet Haematology, The, ISSN 2352-3026, 2015, Volume 2, Issue 6, pp. e251 - e259
Journal Article
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, ISSN 0277-0008, 12/2012, Volume 32, Issue 12, pp. 1070 - 1077
Journal Article
Journal Article
Bone Marrow Transplantation, ISSN 0268-3369, 07/2010, Volume 45, Issue 7, pp. 1147 - 1153
BEAM is a widely used conditioning regimen for relapsed/refractory lymphoma patients undergoing auto-SCT. We conducted a multicenter study with an alternative... 
2 NITROSOUREAS | BONE-MARROW-TRANSPLANTATION | auto-SCT | PREPARATIVE REGIMENS | BEAM CHEMOTHERAPY | FEAM | IMMUNOLOGY | GLUTATHIONE-REDUCTASE ACTIVITY | TRANSPLANTATION | carmustine | BEAM | fotemustine | ONCOLOGY | MULTIPLE-MYELOMA PATIENTS | conditioning | NON-HODGKINS-LYMPHOMA | HIGH-DOSE CHEMOTHERAPY | RAT-BRAIN | STEM-CELL TRANSPLANTATION | HEMATOLOGY | Nitrosourea Compounds - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Middle Aged | Male | Transplantation, Autologous | Hematopoietic Stem Cell Transplantation - mortality | Feasibility Studies | Young Adult | Lymphoma - therapy | Adult | Transplantation Conditioning - adverse effects | Transplantation Conditioning - methods | Etoposide - administration & dosage | Graft Survival | Survival Rate | Treatment Outcome | Cytarabine - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - toxicity | Melphalan - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Aged | Organophosphorus Compounds - administration & dosage | Hematopoietic Stem Cell Transplantation - methods | Kinetics | Antimitotic agents | Care and treatment | Patient outcomes | Dosage and administration | Transplantation | Research | Non-Hodgkin's lymphomas | Antineoplastic agents | Health aspects | Hodgkin's disease | Hematopoietic stem cells | Index Medicus
Journal Article
AMERICAN JOURNAL OF HEMATOLOGY, ISSN 0361-8609, 10/2014, Volume 89, Issue 10, pp. 964 - 968
Despite being considered good-risk acute myelogenous leukemia (AML), long term outcomes in core binding factor (CBF) AML suggest room for improvement. We... 
GENE-MUTATIONS | SURVIVAL | YOUNGER PATIENTS | PROGNOSTIC IMPACT | C-KIT MUTATIONS | REPETITIVE CYCLES | HIGH-DOSE CYTARABINE | ACUTE MYELOID-LEUKEMIA | HEMATOLOGY | MINIMAL RESIDUAL DISEASE | CHEMOTHERAPY
Journal Article
Journal of Cellular and Molecular Medicine, ISSN 1582-1838, 06/2014, Volume 18, Issue 6, pp. 1081 - 1086
The overall response rates and long‐term survival of primary central nervous system lymphoma (PCNSL) are still significantly inferior to the results achieved... 
stereotactic brachytherapy | R‐IDARAM | diffuse large B‐cell lymphoma | primary central nervous system lymphoma | Primary central nervous system lymphoma | Stereotactic brachytherapy | R-IDARAM | Diffuse large B-cell lymphoma | PRIMARY CNS LYMPHOMA | STEREOTACTIC I-125 BRACHYTHERAPY | MEDICINE, RESEARCH & EXPERIMENTAL | RESPONSE CRITERIA | HIGH-DOSE METHOTREXATE | REGIMEN | TOXICITY | diffuse large B-cell lymphoma | CHEMOTHERAPY | RADIATION-THERAPY | CELL BIOLOGY | IMMUNOCOMPETENT PATIENTS | NON-HODGKINS-LYMPHOMA | Dexamethasone - administration & dosage | Prognosis | Humans | Middle Aged | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Rituximab | Central Nervous System Neoplasms - therapy | Male | Chemoradiotherapy | Cytarabine - administration & dosage | Multimodal Imaging | Central Nervous System Neoplasms - pathology | Lymphoma - therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Female | Idarubicin - administration & dosage | Lymphoma - pathology | Methotrexate - administration & dosage | Neoplasm Staging | Care and treatment | Chemotherapy | Anthracyclines | Dexamethasone | Central nervous system | Lymphomas | Methotrexate | Radiotherapy | Cancer | Radiation therapy | Toxicity | Schedules | Spinal cord | Brain cancer | Nervous system | Neurosurgery | Neurotoxicity | Cytarabine | Efficiency | Remission | Brachytherapy | Iodine | Survival | Patients | Lymphoma | Lymphocytes B | Combined treatment | Hodgkin's disease | Tumors | Original
Journal Article